Canada: Canadian Court Decision Places Broad Class Of Patents In Jeopardy

Originally published in Washington Legal Foundation Legal Backgrounder, July 13, 2007

A disturbing recent decision from the Federal Court of Canada, Eli Lilly Canada Inc. v. Novopharm Ltd., calls into question the validity of many patents in the pharmaceutical and chemical fields.1 The decision, which threatens to escape timely appellate review, dramatically alters the patent disclosure requirements in a way that conflicts with global patent practice and Canada’s international treaty obligations.

The Court Decision

The case involves Lilly’s patent on "olanzapine" — a safe, atypical antipsychotic drug discovered after a 15-year search in a previously described class containing millions of individual chemical compounds. The wholly nonobvious constellation of advantageous properties possessed by this "selection invention" had long been sought in the prior art.

The Canadian olanzapine patent was nonetheless found to be deficient. The defect was not lack of novelty, utility, or inventive step, or failure to teach how to make and use the invention, or even failure to identify in the patent text the newly discovered properties that made olanzapine patentable. Instead, the fatal deficiency was said to lie in the failure to include in the text of the patent application the underlying data and protocols, embodied in thousands of pages of experimental records, proving the existence of these properties.2 In essence, the court created a "super-sufficiency" disclosure requirement for selection inventions in Canada and then found it not satisfied, thus allowing immediate regulatory approval of Novopharm’s competing generic product. The court’s rejection of the textual description of the advantages of olanzapine as "simply rhetoric"3 conflicts with well-settled legal principles not only in Canada but throughout the rest of the developed world and represents a repudiation of Canada’s obligations under the Patent Cooperation Treaty (PCT) and other international agreements.

Patents and Drugs

Patent systems are designed to reward the successful search for that which is new and useful where reasonable predictability is lacking. There is no field of human endeavor more fraught with unpredictability and opportunities for failure, nor more important to the well-being of society, than the development of medicines for human use. Successful drugs must combine therapeutic efficacy and safety in one of nature’s most complicated and least understood systems — the living human being. Ultimate success in this area often comes as a result of painstaking sifting through mountains of chaff represented by generally known classes of compounds in the search for the few grains of wheat — individual molecules in which these twin qualities are combined. Thus, a moment of intellectually honest reflection compels the recognition that a viable research-based pharmaceutical industry is essential to meet the health challenges of the future and that a fair and reliable patent system is crucial to the viability of the pharmaceutical industry. Abandonment of well-settled legal principles and international treaty obligations resulting in premature generic competition is antithetical to these objectives.

Selection Inventions in the Pharmaceutical Industry

When Isaac Newton developed the laws of motion in the 17th century, he acknowledged that he did so "by standing upon the shoulders of [the scientific] Giants" that preceded him.4 It is thus with all important inventions, and particularly so in pharmaceutical research and development.

In the search for new medicines, the first step is the development of new chemistries that permit the manufacture of new classes of compounds. Due to the complexity of the organic molecules used in medicine, the discovery of a new class of molecules not uncommonly comprehends within its scope millions and millions of possible variations on the new theme. But the discovery of a new class of compounds, like Columbus’ discovery of the New World, only opens the door for further exploration of the territory. Just as long and tedious searching within the confines of the new continent led years later to the discovery of gold in California, so too can long and tedious searching among the members of the newly discovered class of compounds be required to find the one molecule within that new territory that is particularly useful as a human medicine.

This is a so-called selection invention. When the search for it is undertaken by many, punctuated by repeated failure over many years, and yields a unique and desirable constellation of properties that could not have been predicted based on chemical structure, such a selection invention has, until now, uniformly been recognized as patentable.

Olanzapine — A Prototypical Selection Invention

The development of olanzapine, briefly summarized here, has been extensively documented in previous judicial decisions.5 Since the early 1970s, the entire industry had been searching for a safe, atypical antipsychotic drug — one that could treat the symptoms of schizophrenia without causing the horrible movement disorders that resulted from administration of typical antipsychotic drugs and without causing a variety of intolerable side effects. The first atypical antipsychotic drug — clozapine —was found to destroy white blood cells in some patients, leading to a number of deaths in early clinical trials. In the ensuing search for a replacement, a host of new classes of compounds were naively described in the literature as putative antipsychotic drugs. One-by-one, however, all the development candidates drawn from these classes of compounds failed in the clinic, either for lack of efficacy or lack of safety.

The prior art in this case was such a 1970s-vintage patent filed by Lilly based on the identification of a new class of compounds then thought on the basis of animal tests to have antipsychotic activity. Consistent with the experience of the rest of the industry, however, the two most promising candidates selected from this class both failed. One led to white blood cell problems in animal tests and the other led to elevated liver and muscle enzymes that forced its withdrawal from clinical trials.

By 1990, it was clear that the chemical properties that yielded atypical antipsychotic efficacy were unknown, as were the chemical properties that led to the host of unwanted side effects in failed drug candidates. Small structural changes in these chemicals were known to yield dramatic and unpredictable changes in properties, whereby the only way to confirm that a safe, atypical antipsychotic drug had been developed was to test it in actual human schizophrenia patients.

In a last ditch effort to find such a molecule, Lilly selected olanzapine — one of the millions of compounds encompassed by the class originally described in the 1970s — for such a test. The initial clinical trials of olanzapine revealed that it was an effective antipsychotic drug, less likely to cause movement disorders in the clinic, with no negative effect on white blood cells, and with an apparently reduced effect on liver and muscle enzymes. A patent application describing the structure of olanzapine, the method of making and using it, and this unique set of properties was promptly filed. Olanzapine went on to become one of the most widely prescribed antipsychotic drugs in the world. Based on thousands of pages of additional evidence constituting the underlying data establishing the properties of olanzapine, the validity of both the U.S.6 and Canadian7 olanzapine patents has previously been sustained.

The Decision Conflicts with Existing Law and Treaty Obligations

Patent applications were never intended to be encyclopedias of all the evidence establishing patentability. They are instead the vehicle by which the inventor teaches persons who are already skilled in the technology to which the invention relates how to make and use the invention. The most that has ever been required regarding the usefulness of the drug or beneficial properties of the drug upon which patentability is predicated is a statement in the application of what those utilities and properties are. If the utility of the invention, or the adequacy of the disclosure, or the existence of an inventive step were called into question either during the patent procurement process or in subsequent enforcement proceedings, it has always been the tradition in the developed world that additional evidence bearing on these issues would be received.

These requirements for a sufficient disclosure are so well settled that they have been embodied in the PCT, which has been in force for more than 25 years and to which 137 countries, including Canada, Great Britain, the United States, Japan, and virtually the entire European community are signatories. The requirements for the description of the invention in an application under the PCT are explicitly and succinctly set forth in Article 5: "The description shall disclose the invention in a manner sufficiently clear and complete for the invention to be carried out by a person skilled in the art."

As a signatory to the PCT, Canada is obliged not to impose additional requirements for an adequate patent disclosure beyond those required by the PCT. Article 27(1) explicitly states: "No national law shall require compliance with requirements relating to the form or contents of the international application different from or additional to those which are provided for in this Treaty and the Regulations."

If further evidence supporting the asserted beneficial properties of the claimed invention is to be required, it is clear that signatories to the PCT cannot require that information to be contained in the patent application itself but may instead require that any needed additional evidence be submitted separately. This is abundantly clear from Article 27(6), which states: "The national law may require that the applicant furnish evidence in respect of any substantive condition of patentability prescribed by such law."

Indeed, this has been the custom and practice in Canada, the United States, and the European community for decades prior to this decision. In the European Patent Office, "[t]he relevant arguments and evidence to be considered by the examiner for assessing inventive step may either be taken from the originally-filed patent application or submitted by the applicant during the subsequent proceedings . . . ."8 Like other jurisdictions, the U.K. court has held that the advantages must be identified, but such identification does not require proof by comparative data.9 In the United States, advantages of the invention are to be described in the patent application,10 but rules and detailed examination procedures provide for submission of evidence supporting the asserted advantages by declaration.11

Beyond the foregoing, the Canadian court’s adoption of a "super-sufficiency" disclosure requirement in the area of pharmaceutical chemistry appears also to violate Canada’s obligations under Article 27.1 of the Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS). That agreement requires that "patents shall be available and patent rights enjoyable without discrimination as to . . . the field of technology."

Left uncorrected, it will soon become clear that the Canadian court has painted with too broad a brush. The rule it has announced will actually invalidate hundreds if not thousands of extant patents in a whole spectrum of unpredictable technologies. In the chemical, biological, agricultural, and paper industries, for example, selection inventions are also ubiquitous. The inability reasonably to predict the impact on important industrial products and processes of changes in the nature of materials used in them spawns trial and error experimentation and resulting selection inventions. If members of these industries are not distressed by this decision, they are simply not paying attention.

The Need for Appellate Review

The negative impact of this ruling is multiplied by the procedural posture of the case. If an immediate appeal is denied, the decision is tantamount to the wrongful grant of a compulsory license to a valid and hugely valuable patent. This case arises under Canada’s Patented Medicines Act, Section 55.2, which provides summary proceedings to determine whether a generic manufacturer’s allegation of invalidity is justified. If the court rules in favor of the innovator, an appeal by the generic manufacturer can be heard. However, if the court rules in favor of the generic interest, the Minister of Health is free to issue immediate marketing authorization for the generic product. In the past, the Canadian courts have held that once the Minister has approved the generic product the appeal of the ruling in a Section 55.2 action becomes moot, the only recourse being to commence patent infringement proceedings. Because such proceedings commonly last many years and often consume the entire remaining patent term, the exclusive marketing right the patent was to have conveyed is irretrievably lost. This procedure stands in stark contrast to the procedural protections available under the Hatch-Waxman Act in the United States. There, a decision in favor of the generic manufacturer is immediately appealable. Surely, this is a case where the Canadian appellate court can and should exercise its discretion to address promptly whether this new patentability requirement imposed by this court decision has placed Canada in non-compliance with its treaty obligations.


The consequences of the court’s decision in Eli Lilly Canada Inc. v. Novopharm Ltd. are far-reaching. Many industries rely on selection invention patents, now of doubtful validity in Canada, to protect their innovations. Further, as this case sets out a new and separate disclosure standard for such patents, it violates both the non-discrimination requirements of TRIPS and the disclosure requirements of the PCT. Hopefully, the appeals court will use its discretion to resolve this matter. Otherwise, it will be up to the Canadian Parliament to get Canada back on the right track.


1. Eli Lilly Canada Inc. v. Novopharm Ltd. (June 5, 2007, Citation 2007 FC 596, Docket T-1532-05). The full text is available at

2. Id. at paragraphs 152-162.

3. Id.

4. Letter to Robert Hooke, Feb. 5, 1676.

5. See notes 6 and 7, infra.

6. Eli Lilly & Co. v. Zenith Goldline Pharms. Inc., 364 F. Supp. 2d 820 (N.D. Ind. 2005), aff’d, 471 F.3d 1369 (Fed. Cir. 2006).

7. Eli Lilly Canada Inc. v. Apotex Inc., 2007 FC 455 (2007).

8. Guidelines for Examination in the EPO, Part C, Chapter IV, 9.11.

9. See TERRELL ON THE LAW ON PATENTS (16th ed. Sweet and Maxwell, London, 2006), at 294.

10. In re Davies, 475 F.2d 667 (C.C.P.A. 1973).

11. 37 C.F.R. § 1.132; Manual of Patent Examining Procedure §§ 716.01-716.06.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on

Click to Login as an existing user or Register so you can print this article.

Events from this Firm
11 Dec 2017, Seminar, Washington, DC, United States

Finnegan partner Lily Lim will present “Tech Talk: Data Privacy Ownership & Ethics” at MassTLC’s seminar, The Intersection of IoT and Robotics: How Sensors, Data, and Intelligence Are Redefining Industry.

12 Dec 2017, Seminar, Edinburgh, UK

Finnegan partner Anthony Tridico will present “U.S. Patent Case Law Update” at the Chartered Institute of Patent Attorneys’ annual Patent Case Law Review.

12 Dec 2017, Webinar, Washington, DC, United States

As part of CompuMark’s webinar series, Finnegan partner Doug Rettew will discuss trademark laws impacting brand protection and enforcement.

In association with
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:
  • To allow you to personalize the Mondaq websites you are visiting.
  • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our information providers who provide information free for your use.
  • Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.
    If you do not want us to provide your name and email address you may opt out by clicking here
    If you do not wish to receive any future announcements of products and services offered by Mondaq you may opt out by clicking here

    Terms & Conditions and Privacy Statement (the Website) is owned and managed by Mondaq Ltd and as a user you are granted a non-exclusive, revocable license to access the Website under its terms and conditions of use. Your use of the Website constitutes your agreement to the following terms and conditions of use. Mondaq Ltd may terminate your use of the Website if you are in breach of these terms and conditions or if Mondaq Ltd decides to terminate your license of use for whatever reason.

    Use of

    You may use the Website but are required to register as a user if you wish to read the full text of the content and articles available (the Content). You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these terms & conditions or with the prior written consent of Mondaq Ltd. You may not use electronic or other means to extract details or information about’s content, users or contributors in order to offer them any services or products which compete directly or indirectly with Mondaq Ltd’s services and products.


    Mondaq Ltd and/or its respective suppliers make no representations about the suitability of the information contained in the documents and related graphics published on this server for any purpose. All such documents and related graphics are provided "as is" without warranty of any kind. Mondaq Ltd and/or its respective suppliers hereby disclaim all warranties and conditions with regard to this information, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Mondaq Ltd and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use or performance of information available from this server.

    The documents and related graphics published on this server could include technical inaccuracies or typographical errors. Changes are periodically added to the information herein. Mondaq Ltd and/or its respective suppliers may make improvements and/or changes in the product(s) and/or the program(s) described herein at any time.


    Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:

    • To allow you to personalize the Mondaq websites you are visiting.
    • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
    • To produce demographic feedback for our information providers who provide information free for your use.

    Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.

    Information Collection and Use

    We require site users to register with Mondaq (and its affiliate sites) to view the free information on the site. We also collect information from our users at several different points on the websites: this is so that we can customise the sites according to individual usage, provide 'session-aware' functionality, and ensure that content is acquired and developed appropriately. This gives us an overall picture of our user profiles, which in turn shows to our Editorial Contributors the type of person they are reaching by posting articles on Mondaq (and its affiliate sites) – meaning more free content for registered users.

    We are only able to provide the material on the Mondaq (and its affiliate sites) site free to site visitors because we can pass on information about the pages that users are viewing and the personal information users provide to us (e.g. email addresses) to reputable contributing firms such as law firms who author those pages. We do not sell or rent information to anyone else other than the authors of those pages, who may change from time to time. Should you wish us not to disclose your details to any of these parties, please tick the box above or tick the box marked "Opt out of Registration Information Disclosure" on the Your Profile page. We and our author organisations may only contact you via email or other means if you allow us to do so. Users can opt out of contact when they register on the site, or send an email to with “no disclosure” in the subject heading

    Mondaq News Alerts

    In order to receive Mondaq News Alerts, users have to complete a separate registration form. This is a personalised service where users choose regions and topics of interest and we send it only to those users who have requested it. Users can stop receiving these Alerts by going to the Mondaq News Alerts page and deselecting all interest areas. In the same way users can amend their personal preferences to add or remove subject areas.


    A cookie is a small text file written to a user’s hard drive that contains an identifying user number. The cookies do not contain any personal information about users. We use the cookie so users do not have to log in every time they use the service and the cookie will automatically expire if you do not visit the Mondaq website (or its affiliate sites) for 12 months. We also use the cookie to personalise a user's experience of the site (for example to show information specific to a user's region). As the Mondaq sites are fully personalised and cookies are essential to its core technology the site will function unpredictably with browsers that do not support cookies - or where cookies are disabled (in these circumstances we advise you to attempt to locate the information you require elsewhere on the web). However if you are concerned about the presence of a Mondaq cookie on your machine you can also choose to expire the cookie immediately (remove it) by selecting the 'Log Off' menu option as the last thing you do when you use the site.

    Some of our business partners may use cookies on our site (for example, advertisers). However, we have no access to or control over these cookies and we are not aware of any at present that do so.

    Log Files

    We use IP addresses to analyse trends, administer the site, track movement, and gather broad demographic information for aggregate use. IP addresses are not linked to personally identifiable information.


    This web site contains links to other sites. Please be aware that Mondaq (or its affiliate sites) are not responsible for the privacy practices of such other sites. We encourage our users to be aware when they leave our site and to read the privacy statements of these third party sites. This privacy statement applies solely to information collected by this Web site.

    Surveys & Contests

    From time-to-time our site requests information from users via surveys or contests. Participation in these surveys or contests is completely voluntary and the user therefore has a choice whether or not to disclose any information requested. Information requested may include contact information (such as name and delivery address), and demographic information (such as postcode, age level). Contact information will be used to notify the winners and award prizes. Survey information will be used for purposes of monitoring or improving the functionality of the site.


    If a user elects to use our referral service for informing a friend about our site, we ask them for the friend’s name and email address. Mondaq stores this information and may contact the friend to invite them to register with Mondaq, but they will not be contacted more than once. The friend may contact Mondaq to request the removal of this information from our database.


    From time to time Mondaq may send you emails promoting Mondaq services including new services. You may opt out of receiving such emails by clicking below.

    *** If you do not wish to receive any future announcements of services offered by Mondaq you may opt out by clicking here .


    This website takes every reasonable precaution to protect our users’ information. When users submit sensitive information via the website, your information is protected using firewalls and other security technology. If you have any questions about the security at our website, you can send an email to

    Correcting/Updating Personal Information

    If a user’s personally identifiable information changes (such as postcode), or if a user no longer desires our service, we will endeavour to provide a way to correct, update or remove that user’s personal data provided to us. This can usually be done at the “Your Profile” page or by sending an email to

    Notification of Changes

    If we decide to change our Terms & Conditions or Privacy Policy, we will post those changes on our site so our users are always aware of what information we collect, how we use it, and under what circumstances, if any, we disclose it. If at any point we decide to use personally identifiable information in a manner different from that stated at the time it was collected, we will notify users by way of an email. Users will have a choice as to whether or not we use their information in this different manner. We will use information in accordance with the privacy policy under which the information was collected.

    How to contact Mondaq

    You can contact us with comments or queries at

    If for some reason you believe Mondaq Ltd. has not adhered to these principles, please notify us by e-mail at and we will use commercially reasonable efforts to determine and correct the problem promptly.

    By clicking Register you state you have read and agree to our Terms and Conditions